Sorry, you need to enable JavaScript to visit this website.

Sign Up For Mailing List Button

Donate to Genetic Alliance

Disease Search Button

Navigating the Ecosystem of Translational Science (NETS)

Facebook icon
Twitter icon
LinkedIn icon
Click on concepts to view information and resources. Let us know if you are aware of others we should add.
Hypotheses Disease Pathophysiology Therapeutic Targets Cell Lines Animal Models Biorepositories Basic Science Biomedical Informatics Data Repository Genotypes Phenotypes Molecular Pathway HTS Assay Hits Approved Compound Assay Development Compound Libraries HTS System Misses Unapproved Compounds (NCE/NME) Lead Compounds Compounds for Preclinical & Clinical Studies Chemistry, Manufacturing & Control Therapeutic Discovery & Nonclinical Research Medicinal Chemistry & Biological Development Non-GLP Studies Acute Toxicology In vitro & In vivo Pharmacology Safety Dose Efficacy & Proof of Concept cGMP Manufacturing GLP Preclinical Studies PK (ADME) Pharmacology Long Term Toxicology (Ongoing) Sustained Product Availability Approved Therapy IND Application HAs: Reporting Meetings Amendments NDA or BLA Rejected Application New Indication Insurance Coverage & Reimbursement Incorporation into Clinical Practice Registries Clinical Cohorts Identification of Subpopulations Clinical Cohort Development, Clinical Research, Regulatory Requirements and Market Access Researcher/Investigator IRB Approval Recuitment Informed Consent Dynamic Reconsent Participant Enrollment Updated Natural History Standard of Care Access to Therapies Incorporation into Clinical Practice Phase 4 (Post-Marketing) Responder, Non-responder Study Sponsor Contractual & Legal Agreements Qualified Investigator & Study Staff Clinical Trial Natural History Studies Outcome Measures Therapeutic and Clinical Endpoints Clinical Trial Planning & Preparation Trial Design Phase 1 Clinical Trials (PIC, Safety, Dose) Phase 2 Clinical Trials (Safety, Efficacy, Dose) Phase 3 Clinical Trials (Safety, Efficacy) Re-Evaluate or Discontinue Biospecimens NBE Development Purified Protein Biospecimens

* Investigational treatments may be candidates for compassionate use.

† This phase of drug development contributes to epidemiology.


NETS is undergoing an update! Please feel free to leave suggestions or feedback: contact us here.

Follow Us

Twitter icon
Facebook icon
LinkedIn icon
YouTube icon

4301 Connecticut Ave NW, Suite 404, Washington DC 20008-2369 | Tel: 202.966.5557 | Fax: 202.966.8553 | EIN 52-1571905

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution 3.0 License.